Title: Iambic Therapeutics: files amended charter and bylaws after IPO

Short description: Iambic Therapeutics filed an 8-K reporting it filed an amended and restated certificate of incorporation and adopted amended and restated bylaws, effective Oct 16, 2026.

Summary:

What happened

• On Oct 16, 2026, Iambic Therapeutics, Inc. filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the completion of the Company’s initial public offering (the “IPO”).
• Effective as of Oct 16, 2026, the Company adopted amended and restated bylaws (the “Restated Bylaws”) in connection with the completion of the IPO.
• The filing states that descriptions of the Restated Certificate and Restated Bylaws are set forth in the Prospectus filed with the SEC on Oct 15, 2026 pursuant to Rule 424(b) under the Securities Act relating to the Company’s Registration Statement on Form S-1, as amended (File No. 333-299057).

Key details

• Restated Certificate filed with the Delaware Secretary of State on Oct 16, 2026.
• Restated Bylaws adopted, effective Oct 16, 2026.
• Prospectus sections cited: “Risk factors” and “Description of capital stock,” Prospectus filed Oct 15, 2026 under Rule 424(b).
• Regulation FD disclosure: the Company may announce material information through SEC filings, its website (www.iambic.ai), press releases, public conference calls, public webcasts and social media.

Why it may matter

• The filing reports Item 5.03 (amendments to articles of incorporation or bylaws) and Item 7.01 (Regulation FD disclosure about channels for disclosure of material information).
• This filing does not show why the insider traded or why the company acted.